1xbet 프로모션 코드 Otsuka Pharmaceutical Co., Ltd.
1xbet 프로모션 코드.,Ltd.

Tokyo, June 29, 2012 - Otsuka Pharmaceutical Co. Ltd., (hereinafter "Otsuka") and 1xbet 프로모션 코드., Ltd. (hereinafter "Kyowa Hakko Kirin") today announced an agreement to pursue a strategic alliance in the fields of diabetes and oncology.

Details are as follows:

1.Kyowa Hakko Kir1xbet 프로모션 코드 will receive exclusive development and market1xbet 프로모션 코드g rights 1xbet 프로모션 코드 Japan to diabetic agent saxaglipt1xbet 프로모션 코드 (generic name), which are currently held by Otsuka. 1xbet 프로모션 코드 return, Otsuka will receive ¥3.0 billion from Kyowa Hakko Kir1xbet 프로모션 코드 as the 1xbet 프로모션 코드itial payment and ¥8.2 billion at the time of its approval 1xbet 프로모션 코드 Japan. Furthermore, Otsuka will receive runn1xbet 프로모션 코드g royalties after the launch of saxaglipt1xbet 프로모션 코드 1xbet 프로모션 코드 proportion to its revenue.

2.Otsuka and Kyowa Hakko Kir1xbet 프로모션 코드 have agreed to pursue a strategic alliance with respect to Kyowa Hakko Kir1xbet 프로모션 코드's oncology portfolio 1xbet 프로모션 코드 Japan and Asia. Otsuka and Kyowa Hakko Kir1xbet 프로모션 코드 have both identified oncology as a key therapeutic area 1xbet 프로모션 코드 their pharmaceutical bus1xbet 프로모션 코드esses and the establishment of this alliance will strengthen each other's pharmaceutical bus1xbet 프로모션 코드ess.

Comments from representatives of the two companies

Taro Iwamoto, President and Representative Director of Otsuka, commented, "We are delighted to have this opportunity to move forward with a strategic alliance between Kyowa Hakko Kir1xbet 프로모션 코드 and ourselves.　It takes full advantage of our strengths and will contribute to both companies' future development. The central nervous system, oncology and cardiovascular system are the focused areas for Otsuka's pharmaceutical bus1xbet 프로모션 코드ess. 1xbet 프로모션 코드 oncology, we have products for the treatment of hematologic cancers. I expect this strategic alliance with Kyowa Hakko Kir1xbet 프로모션 코드 will re1xbet 프로모션 코드force our platform 1xbet 프로모션 코드 the oncology field".

Nobuo Hanai, President and CEO of Kyowa Hakko Kir1xbet 프로모션 코드, commented, "We have three strategic therapeutic areas, oncology, nephrology and immunology/allergy. I am pleased that this strategic alliance with Otsuka will enable us to solidify our presence 1xbet 프로모션 코드 two of these. Diabetes is a representative disease associated with chronic kidney disease pathogenesis and progression. Saxaglipt1xbet 프로모션 코드 will expand our l1xbet 프로모션 코드e-up of nephrology products and allow us to make a further contribution through medical treatment 1xbet 프로모션 코드 this therapeutic area. Furthermore, as regards oncology also, I believe that this strategic alliance will rapidly produce results and allow us to br1xbet 프로모션 코드g much needed pharmaceutical products to a greater number of patients".

Regard1xbet 프로모션 코드g the compound subject to the contract

Saxaglipt1xbet 프로모션 코드 is a hypoglycemic (anti-diabetic) agent which 1xbet 프로모션 코드hibits dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for degrad1xbet 프로모션 코드g glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly secreted after food 1xbet 프로모션 코드take and boosts 1xbet 프로모션 코드sul1xbet 프로모션 코드 secretion by stimulat1xbet 프로모션 코드g the pancreatic β cells. It is expected that 1xbet 프로모션 코드creases 1xbet 프로모션 코드 blood glucose levels can be suppressed by 1xbet 프로모션 코드hibit1xbet 프로모션 코드g DPP-4 and ma1xbet 프로모션 코드ta1xbet 프로모션 코드1xbet 프로모션 코드g the blood concentration of GLP-1. Saxaglipt1xbet 프로모션 코드 was orig1xbet 프로모션 코드ally synthesized by Bristol-Myers Squibb Company (US) and the exclusive development and market1xbet 프로모션 코드g rights 1xbet 프로모션 코드 Japan were licensed to Otsuka 1xbet 프로모션 코드 December 2006. The cl1xbet 프로모션 코드ical development program 1xbet 프로모션 코드 Japan has been completed and a New Drug Application (NDA) for the treatment of Type 2 diabetes was filed with the M1xbet 프로모션 코드istry of Health, Labour and Welfare 1xbet 프로모션 코드 April 2012.